Solid Biosciences Inc. (SLDB) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago ⓘ · Not investment advice

Solid Biosciences Inc.

SLDB Healthcare Biotechnology📄 SEC filings ↗ CUSIP 83422E204
Valuation N/A
Long-term trend (200d) 41% above 200-day Risk 42/100 Elevated
▾ What's in the 42/100 risk score? (higher = riskier)
Fundamental health (43%) 20/100 → +8.6
leverage 20/100
Smart money (short interest + insider buying) (31%) 79/100 → +24.8
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 33/100 → +8.5
Total42/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.

💵 Price $8.70 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago
📍 START HERE

How to read SLDB (pre-profit growth)

This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.

Where to start — the sections that matter most for this stock
  1. 1 Reverse-DCF — the growth the price demands ↓
    It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
  2. 2 Cash runway ↓
    Can it reach profitability before it has to raise money and dilute shareholders?
  3. 3 Interactive calculator ↓
    Set your own growth + margin assumptions and see what the business would be worth if you are right.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ Using the right valuation lens for this business type

Standard DCF doesn't fit SLDB well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value biotechnology. Reverse DCF + Football Field also work as cross-checks.

ⓘ Why does SLDB trade at $8.70?

Solid Biosciences Inc. has 87.5 million shares outstanding. At $8.70 per share, the market values all outstanding SLDB equity at $761 million. That's market capitalization, not enterprise value — enterprise value also accounts for debt and cash (SLDB carries little or no debt, so the two are close here). The share price by itself tells you almost nothing — a company can pick any share price by splitting or issuing more shares. What matters is the total value (Market Cap?Market Cap — The total dollar value the market is assigning to the entire company.
Why it matters: This is the number that actually matters when comparing companies. Two companies with the same business but different share counts have the same market cap.
Reference: Mega cap >$200B · Large $10–200B · Mid $2–10B · Small $300M–2B · Micro <$300M
Full explanation →) compared to what the business actually produces. This page values SLDB in Per Share?Per Share — A company-level figure divided by total shares — what one share represents.
Why it matters: Per-share metrics are the only way to fairly compare two companies with different share counts.
Full explanation → economics — what each share represents of the underlying business. Play with the share-price calculator on the homepage →

Loading insider & short-seller data…
Checking filings for failure warnings…
VALUATION RANGE — CROSS-METHOD CHECK

Football field: where does the price sit?

Different valuation methods produce different fair-value ranges depending on assumptions. Plotting them together lets you see at a glance whether the current price is reasonable across approaches, or only one specific lens.

$1$3$5$7$9Current price $8.70EV / Sales (p25→p75)$0.96$2.53
The current price sits ABOVE the high end of every method. The market is paying a premium to all of these lenses — it expects materially better growth or margins than the models assume.

Industry multiples sourced from: industry: Biotechnology. See the Peer Basket section below for the peer comparison and its limited-comparables caveat.

PEER BASKET — TIGHT COMPARABLES

How does SLDB stack up against its closest peers?

We take the 8 same-industry companies most similar to SLDB (similar size) and check what investors are paying for each dollar of their revenue (or profits). If SLDB is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, FCF yield (in the table) is usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.

▾ What's "EV / Sales" in plain English?

EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.

EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).

p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.

What peers trade at (p25 / median / p75)

Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.

Peer-implied value check
Not enough clean peer EV/Sales multiples to derive a reliable median (some were dropped as implausible/outliers). The EV/EBIT and FCF-yield rows above are the better read here; also lean on the DCF.

⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.

▾ View peer list (8)
Ticker Company Industry Mcap EV/Sales EV/GPEV/EBIT FCF Yield
REPL Replimune Group, Inc. Biotechnology $718M — —— —
VALN Valneva SE Biotechnology $892M — —— —
PRME Prime Medicine, Inc. Biotechnology $641M 138.4x —— 0.1%
SANA Sana Biotechnology, Inc. Biotechnology $918M — —— —
TECX Tectonic Therapeutic, Inc. Biotechnology $588M — —— —
MGTX MeiraGTx Holdings plc Biotechnology $986M 12.1x —— 1.0%
ZURA Zura Bio Ltd Biotechnology $541M — —— —
KYTX Kyverna Therapeutics, Inc. Biotechnology $518M — —— —
FINANCIAL HEALTH SCREENS

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
Not available for this filer

The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.

Piotroski-style checks (partial — not a standard F-score)
3 passed · 4 failed · 2 n/a
Partial result, not a standard F-score: 3 of 7 measurable checks passed. 2 of the 9 standard checks couldn't be measured, so this is scored out of 7, not 9 — it isn't comparable to a published F-score.
▾ The checks — what passed, what didn't (and what we couldn't measure)
  • ✗ Positive net income
    Net income -$174.3M in FY2025.
    Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
  • ✗ Positive operating cash flow
    Operating cash flow -$156.3M (was -$100.0M the prior year).
    Why this matters: Profit can be an accounting figure; cash from running the business is harder to fake. Negative operating cash flow means the core business consumes cash and must be funded externally.
  • ✓ Cash flow backs up reported profit
    Operating cash flow -$156.3M vs net income -$174.3M.
  • ✗ Return on assets improving
    Return on assets -75.0% vs -66.1% a year ago.
    Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
  • ✓ Debt load (vs assets)
    The filing reports no interest-bearing debt in either year (total assets $232.5M).
  • ✓ Short-term liquidity (current ratio)
    Current ratio 6.14x vs 5.20x a year ago.
  • ✗ Share count (dilution)
    Share count rose 114.4% (40.8M → 87.5M year-over-year).
    Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
  • · Pricing power (gross margin) (n/a — data not reported; not scored)
  • · Sales per asset (asset turnover) (n/a — data not reported; not scored)

Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.

Cash Runway
5 mo
CRITICAL — under 6 months of cash

Plain English: the company holds about $60M in cash and is burning roughly $156M/year in operations. At that pace, the cash lasts 5 mo before it must raise capital (diluting shareholders), take on debt, or cut spending.

Assumes constant burn and ignores financing/asset sales. For pre-profit biotech and growth companies, this matters more than a DCF — a great drug pipeline is worthless if they run out of money before approval.

INTERACTIVE — TWEAK YOUR ASSUMPTIONS

What if you assume different inputs?

Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount Rate?Discount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 10.0%, the figure our model used for SLDB. Open Advanced to also change beta, growth and the rate path.

Note: no headline intrinsic value is published for this stock (the valuation is held for a data-quality reason — see the notes above). The calculator below is a what-if tool: the values it produces are your assumptions played out, not our estimate.

4.5% (risk-free)9-10% normal18% (deep-risk)
0%2-3% (GDP)5% (rarely sustainable)

A full intrinsic value isn't shown for SLDB because the valuation is currently held for a data-quality reason (see the guardrail notes above). The reverse-DCF reading still works — it needs only the price and cash flow — but we won't publish a forward value until the underlying data passes our checks.

For comparison — the revenue growth today's price already assumes
—
—

—

⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Where the discount rate comes from — discount rate = risk-free + beta × equity-risk-premium
What you'd earn risk-free from government bonds — the floor under every other rate. Slide it down to model the market expecting rate cuts (value rises); up for higher-for-longer.
The extra yearly return investors demand for owning stocks instead of safe bonds — the price of risk. History runs ~4.5–6.5%; we default to 5.5% (slightly conservative). It's an estimate, not a law — lower it if you think equities are less risky than that.
Inflation reduces the purchasing power of a nominal return: a 9% gain at 3% inflation is about 6% in real terms. The intrinsic value above is already in today's dollars (a nominal DCF carries inflation in both the growth and the discount rate), so this switch does not change the value — it restates the return in real terms.
Higher beta → higher discount rate (sets the rate above). 1.0 = moves with the market.
What you think SLDB can grow revenue for ~5 years, then fades to terminal.
For a pre-profit company: the % of revenue that eventually becomes free cash flow once mature. (Our published value uses the sector norm.)
All inputs start at the values our model used.

    Copy shareable link to this scenario →

    Price$8.70
    Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

    A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
    Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
    Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
    Full explanation →     (DCF) valuation is not meaningful for Solid Biosciences Inc. because the company exhibits negative net income and operating cash flow, indicating it is not yet profitable. Valuing SLDB would require projecting the success and commercialization of its drug pipeline, which is highly speculative. Investors are likely betting on the potential for future drug approvals and market penetration. The primary quantifiable risk is the continued negative operating cash flow, which implies ongoing cash burn and potential need for further capital raises.

    ⚠️ FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.

    As of 3 months ago

    ANATOMY

    Anatomy of a share

    What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

    SLDB Solid Biosciences Inc. stock anatomy showing per-share revenue, operating expenses, free cash flow, and debt
    Revenue figure looks incomplete. Net income divided by the revenue we parsed gives a -1,062% margin, which no operating business earns — the revenue tag we read is almost certainly a fragment (a fee line or a single segment), not consolidated sales. We are not drawing the margin breakdown from it, and revenue-per-share on this page should be treated as unreliable until the filing's total-revenue tag resolves.
    Plain English: each share (at $9) represents revenue that isn't reported in machine-readable form for this filer (so no revenue-per-share figure here), $1.99 lost per share per year, and $1.99 of cash burned per share (negative free cash flow) from the latest fiscal year. The filing reports no interest-bearing debt — the 52.5M of total liabilities on the balance sheet are operating items (payables, leases, deferred taxes), not borrowings.
    What's free cash flow / what do these mean?

    Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.

    Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.

    Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.

    Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.

    THE KEY DEBATE

    What you actually need to decide

    Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

    🐂 The Bull Case
    For the stock to work, clinical trials for its lead gene therapy candidate must demonstrate significant efficacy and safety, leading to regulatory approval and eventual commercialization.
    🐻 The Bear Case
    The biggest fundamental risk is the continued negative operating cash flow, which implies ongoing cash burn and could lead to significant shareholder dilution if further capital raises are needed without a clear path to profitability.
    📌 Signposts to watch — update your view as these print
    • Results from ongoing or planned clinical trials
    • Updates on regulatory interactions or submissions
    • Announcements of strategic partnerships or financing rounds
    MOMENTUM — WHAT'S GETTING BETTER & WORSE

    The trend, in plain numbers (FY2024 → FY2025, latest reported)

    Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

    ⚠ Worsening
    • Free cash flow is negative at -$174.4M — the cash burn widened vs last year.
    • Still unprofitable at -$174.3M — loss widening.

    Nothing was clearly improving year-over-year.

    WHO

    Management & Leadership

    Gaurav Shah, M.D. has served as the President and CEO of Solid Biosciences Inc. since 2018. He also holds the position of Chairman of the Board. Prior to Solid Biosciences, Dr. Shah held leadership roles at various biotechnology and pharmaceutical companies.

    Gaurav Shah
    President and Chief Executive Officer
    Ian Smith
    Chief Financial Officer
    WHAT

    What They Make

    Solid Biosciences Inc. is a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD). Their primary product candidates are gene therapies aimed at addressing the underlying genetic cause of the disease.

    End Markets

    Gene TherapyRare DiseasesNeuromuscular Disorders

    Revenue Drivers

    Product pipeline success
    Clinical trial outcomes
    Regulatory approvals
    Market Cap: 761.3MBeta: 1.80
    WHY

    Why Is It Priced Like This?

    Why Customers Pay

    Potential to treat Duchenne muscular dystrophy
    Addresses an unmet medical need
    Offers a disease-modifying therapeutic approach
    No discounted-cash-flow value for this filer This company's reported free cash flow is negative, so a discounted-cash-flow valuation has no positive cash stream to discount. That is a fact about the business, not missing data — the reported figures below are complete.

    What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

    The market is pricing SLDB based on the future potential of its drug pipeline, rather than current cash flows, as evidenced by its negative net income and operating cash flow. The market may be assigning value to the potential for successful clinical trial outcomes and regulatory approval of its gene therapy candidates, which is not in the model. Investors are likely focused on the progress of its clinical programs and cash runway (current ratio 6.14 is adequate) to fund operations until potential commercialization.

    HOW

    Business Model & Valuation

    How They Make Money

    Research and development of gene therapies
    Clinical trials for drug candidates
    Potential future sales of approved therapies

    The company funds its operations primarily through equity raises, as it has negative operating cash flow and does not pay dividends or engage in buybacks.

    Growth / Revenue DCF

    Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.

    Show advanced inputs
    Revenue Growth15.0%

    What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project product, services and recurring/cloud lines independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

    WHEN

    Maturity & Competitive Position

    Growth-stage life sciences

    Moat Signals

    Proprietary gene therapy platforms
    Specialized focus on Duchenne muscular dystrophy
    Intellectual property around drug candidates

    Net income has been negative in the latest period and 0/5 years profitable, with operating cash flow also negative in the latest period and 0/5 years positive.

    WHERE

    Geography & Markets

    Solid Biosciences Inc. is headquartered in the United States, with its research and development activities primarily conducted domestically. As a biotechnology company, its potential market for therapies would be global, though specific geographic revenue mix is not available.

    Geographic Risks

    Regulatory approval risk (FDA, EMA, etc.)
    Clinical trial failure risk
    SIGNALS

    Market Signals

    These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

    Model neutral, tape neutral - aligned.
    RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
    Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
    Reference: 30–70 normal · >70 overbought · <30 oversold
    Full explanation →     (14)    53.1NeutralMomentum is balanced — neither overbought nor oversold.
    MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
    Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
    Reference: Line above signal = bullish momentum · below = bearish
    Full explanation →    BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
    50-Day Average$7.42Price above (+17.3%)Price above its 50-day average = near-term uptrend.
    200-Day Average$6.19Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
    50 vs 200 CrossGolden50-day above 200-dayA "golden cross" — the medium trend has overtaken the long trend (often read as bullish).

    Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

    QUALITY

    Data Quality & Risk Flags (4 notes — click to expand/collapse)
    Guardrail Notes (4)
    • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
    • INVARIANT: weighted IV is non-positive. Model may not be appropriate.
    • Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
    • Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
    FINANCIALS

    Financial Statements (5-year tables — click to expand)

    From Solid Biosciences Inc.'s SEC filings (EDGAR).

    Income (5yr)

    YearRevenueNet IncomeEPS
    2025—-174.3M$-1.99
    2024—-124.7M$-3.06
    2023—-96.0M$-4.83
    20228.1M-86.0M$-10.10
    202113.6M-72.2M$-10.14

    Cash Flow (5yr)

    YearOperating CFCapEx− SBC & adj.Free Cash Flow
    2025 -156.3M 1.2M 16.9M -174.4M
    2024 -100.0M 654,000 10.5M -111.2M
    2023 -94.2M 1.5M 7.6M -103.3M
    2022 -98.0M 3.0M 7.5M -108.5M
    2021 -77.8M 1.3M 13.4M -92.4M

    How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: -156.3M − 1.2M − 16.9M (SBC & adj.) = -174.4M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.

    Balance Sheet

    Total Assets232.5M
    Total Liabilities52.5M
    Equity180.0M
    YOU MIGHT ALSO LIKE

    Similar companies worth a look

    Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

    PG
    Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
    ⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
    ← Browse Stocks See sector peers →
    🔔 Follow $SLDB — free insider alerts
    One email when an insider buys $SLDB on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.